Journal article
Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials
C Seshadri, JAL Flynn, P Maiello, D Schnappinger, RJ Wilkinson, SB Gordon, HC Mwandumba, KC Jambo, DF Hoft, EJ Rubin, E Jamrozik, SM Fortune, JG Kublin
Lancet Microbe | Published : 2026
Open access
Abstract
Controlled human infection models (CHIMs) can accelerate vaccine development for infectious diseases. Mycobacterium tuberculosis is a human-adapted pathogen that is the leading infectious cause of death worldwide. M tuberculosis infection results in a spectrum of clinical outcomes that are incompletely modelled in animals. To date, the risks of infection, prolonged treatment, and sequelae related to CHIMs with M tuberculosis have been considered ethically unacceptable. However, recent advances in bacterial engineering have resulted in safe strains that could permit M tuberculosis CHIM studies with reduced risks. In this Personal View, we address the practical considerations for conducting a ..
View full abstractGrants
Awarded by Wellcome Trust